Search

Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals

Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...

Intraocular lens technology to deliver enhanced optical performance after cataract refractive surgery

Modern cataract surgery aims to provide patients with the best possible visual outcome with the least dependence on spectacles and minimal or no complications and to treat both cataract and refractive errors with a single procedure. Phacoemulsification is the standard...

25 years of OCT

David Huang first described optical coherence tomography (OCT) in 1991, in his seminal paper on the subject in Science. This method developed the work of others on ophthalmic interferometry, which essentially showed that measuring reflected light could be used to...

Optimising the ocular surface by managing meibomian gland dysfunction

Meibomian gland dysfunction (MGD) is ubiquitous. Ocular surface inflammation and irritation are prevalent in most ophthalmology clinics: corneal, cataract, glaucoma, oculoplastic, paediatric, vitreo-retinal, medical retina and refractive surgery. These patients also represent roughly one third of those attending for emergency...

Myasthenia gravis presenting with isolated ptosis: a poorly studied subgroup

Investigation into the cause of one isolated symptom or sign can be challenging if that particular sign may be caused by a variety of pathological processes, affecting different tissues, and presenting to different specialties. Unilateral ptosis is a case in...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

The use of toxin in paediatric strabismus

Strabismus is a common condition that affects up to 5% children and can be associated with abnormal visual development, double vision, loss of depth perception and impaired binocularity [1]. It can also cause cosmetic concerns, negatively impact psychosocial wellbeing and...

Land Ahoy! An interview with Geoff Hilton-Barber

It was during a previous interview with Miles Hilton-Barber [1] that I discovered that his older brother, Geoff, had been an inspiration to him. He informed me that Geoff was also blind from retinitis pigmentosa (RP) and had built his...

Therapy for limbal stem cell deficiency: cell fate after limbal stem cell transplants

“The beauty of scientific research lies in that the search for answers often yields yet more questions.” A large body of evidence points to the corneoscleral limbal location as the repository of putative epithelial stem cells [1]. Thoft proposed the...

Personalising the management of dry eye disease: TFOS DEWS III updates evidence-based recommendations

Dry eye disease (DED) is a heterogenous condition that arises from various aetiologic factors and leads to tear film instability, ocular surface damage and neurosensory changes. Symptoms of DED include ocular dryness, burning, itching, pain and visual impairment. An evidence-based...